Seagen Inc. Announces Departure of CEO Clay Siegall Amid Allegations of Domestic Violence

Strategic Insights -

Seagen Inc., a leading biotechnology company, has filed a Current Report with the Securities and Exchange Commission on May 9, 2022, announcing the departure of its President, Chief Executive Officer, and Chairman, Clay Siegall, Ph.D., due to allegations of domestic violence. According to the report, Dr. Siegall has taken a leave of absence from the company, and an independent committee of the Board of Directors is conducting a thorough investigation into the allegations.

Dr. Siegall has denied the allegations and has informed the company that he is engaged in a divorce. The company's Board of Directors has appointed Roger Dansey, M.D., the company's Chief Medical Officer, as the Interim Chief Executive Officer. Dr. Dansey has served as the company's Chief Medical Officer since May 2018 and has over 30 years of experience in the biotechnology industry.

Key Takeaways:

  • Seagen Inc. has filed a Current Report with the Securities and Exchange Commission on May 9, 2022, announcing the departure of CEO Clay Siegall amid allegations of domestic violence.
  • Dr. Siegall has taken a leave of absence from the company and has denied the allegations, stating that he is engaged in a divorce.
  • The company's Board of Directors has formed an independent committee to conduct a thorough investigation into the allegations.
  • Roger Dansey, M.D., has been appointed as the Interim Chief Executive Officer, taking over the duties and responsibilities of the company's principal executive officer.
  • Dr. Dansey has served as the company's Chief Medical Officer since May 2018 and has over 30 years of experience in the biotechnology industry.
  • Dr. Dansey will continue to be compensated pursuant to the terms of his existing employment arrangements, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 30, 2022.
  • There are no arrangements or understandings between Dr. Dansey and any other person related to his appointment as Interim Chief Executive Officer.
  • There is no family relationship between Dr. Dansey and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer.

Statistics:

  • The company's stock price has seen a significant drop following the announcement, with the shares trading at $143.45 per share on May 9, 2022.
  • Dr. Siegall has been CEO of Seagen Inc. since 2013 and has been instrumental in the company's growth and success.
  • Dr. Dansey has over 30 years of experience in the biotechnology industry and has served in various leadership roles, including Therapeutic Area Head for Late Stage Oncology at Merck & Co.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Seagen Inc. (Exact name of Registrant as specified in its charter) Delaware 0-32405 91-1874389 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S Employer Identification No.)